Clinical and economic comparison of epoetin alfa and darbepoetin alfa

Morreale, Anthony P.; Lattre, Melissa De; Boggie, Dan; Schaefer, Monica

doi:10.1185/030079904125002964

Cited by 44 publications

(20 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…41 The frequency of dosing might not be related to a drug's half-life, however, because it might be possible that erythropoietin receptor cycle activation on erythroid precursors is more relevant than the terminal half-life. 42 All three erythropoetins have similar clinical efficacy. [43][44][45] Epoetin alfa and darbepoetin alfa are licensed for patients with solid tumors and nonmyeloid malignancies undergoing chemotherapy.…”

Section: Erythropoietinmentioning

confidence: 92%

Cancer-related anemia and recombinant human erythropoietin—an updated overview

et al. 2006

View full text Add to dashboard Cite

For cancer patients, anemia can be a debilitating problem that negatively influences their overall quality of life and worsens their prognosis. The condition is caused either by the cancer itself or by cytotoxic treatment. Anemia is the primary indication for transfusion of red blood cells, but the development of recombinant human erythropoietins (epoetins) provides an alternative to red blood cell transfusions. Treatment with epoetins has been shown to reduce transfusion rates and increase hemoglobin response. There is some evidence that epoetins improve quality of life. It remains unclear, however, whether erythropoietin affects tumor growth and survival, and this area requires further investigation. Data from clinical trials suggest that erythropoietin increases the risk of thromboembolic complications. In the management of anemic patients, physicians should follow closely the dosing recommendations in products' package inserts or the ASCO/American Society of Hematology guidelines. Treatment of patients beyond the correction of anemia, however, has to be regarded as experimental and is potentially harmful, so should only be conducted in clinical trials.

show abstract

Section: Erythropoietinmentioning

confidence: 92%

Cancer-related anemia and recombinant human erythropoietin—an updated overview

et al. 2006

View full text Add to dashboard Cite

show abstract

“…These show consistently that the key pharmacological differences between the erythropoietic proteins are the serum elimination half-life (t 1/2 ), the time taken to reach maximum serum concentration after subcutaneous (SC) administration (T max ) and reticulocyte response [36]. For example, in a study of 21 healthy male volunteers, in which the PK parameters of epoetin beta 100 IU/kg were compared with those of epoetin alfa 100 IU/kg [22], epoetin beta was associated with a significantly greater mean reticulocyte response (12% greater, p<0.05) and significantly delayed SC absorption (41.8% longer, p<0.05) compared with epoetin alfa.…”

Section: Pharmacokinetic Profiles Of the Erythropoietic Proteinsmentioning

confidence: 94%

Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins

Oberhoff

2007

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…A recent cost-minimisation analysis has attempted to compare the costs of epoetin alfa and darbepoetin alfa, by applying US average wholesale prices to dosage data derived from published clinical trials 20 . This analysis reported that epoetin alfa generally resulted in lower treatment costs than darbepoetin alfa.…”

Section: Key Cost Driversmentioning

confidence: 99%